A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Hospital Universitario San Ignacio
Chinese PLA General Hospital
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Sheba Medical Center
Acibadem University
Wuhan Sian Medical Technology Co., Ltd
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Ciusss de L'Est de l'Île de Montréal
Second Affiliated Hospital of Guangzhou Medical University
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
University of Erlangen-Nürnberg Medical School
Proacta, Incorporated
Callisto Pharmaceuticals